Publication | Closed Access
MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2- advanced breast cancer (ABC)
15
Citations
0
References
2019
Year
Breast OncologyOncologyMedicinePhase Iii TrialAromatasePharmacotherapyBreast CancerAnti-cancer AgentNonsteroidal Aromatase InhibitorCancer TreatmentPharmacologyRadiation OncologyCancer ResearchEndocrine-related Cancer
No additional data available for this publication yet. Check back later!